UPDATED: AstraZeneca scores FDA nod for long-term Brilinta use

Carly Helfand

's blood thinner is officially one step closer to living up to the British pharma's $ 3.5 billion ambitions. The FDA has handed down an approval for long-term use of the drug in patients who have previously suffered heart attacks, a label expansion that will keep sales coming beyond the first year of therapy.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS